A Phase I Study of GFH312 in Healthy Chinese Subjects

A Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Study Evaluating the Pharmacokinetics and Safety of GFH312 in Healthy Chinese Subjects

The aim of this study was to evaluate the pharmacokinetic profile and observe the safety of GFH312 after single and multiple administrations in healthy Chinese subjects.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteer
• Intervention / Treatment: Drug: GFH312 100 mg; Drug: GFH312 200 mg; Drug: GFH312 120mg; Other: Placebo

Detailed Description

This study was planned to enroll about 26 healthy subjects, subjects were planned to receive single administration of 100 mg GFH312, single administration of 200 mg GFH312, or multiple administrations of 120 mg GFH312, as well as their matching placebo. Subjects were randomized in 3:1 ratio in the single dose cohorts and in 4:1 ratio in the multiple dose cohort.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China
      • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Voluntarily participate in the study and sign the informed consent;
• Male or female healthy subjects aged 18-55 years (inclusive) (single sex ratio not less than 25% of the sample size of each cohort);
• Body mass index (BMI) between 18-28 kg/m2 (inclusive), and weight ≥ 50kg; BMI = Weight (kg) /[Height (m)]2.
• During the screening period and day 1, patients with normal or abnormal results but no clinical significance based on detailed medical history, comprehensive physical examination, laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead electrocardiogram and vital signs.
• Able to communicate well with researchers, understand and comply with research requirements.

Exclusion Criteria:

• Any procedure or disease that may significantly alter drug absorption, distribution, metabolism, or excretion, or participation in this study may compromise the safety of the subject.
• Tuberculin test positive
• Abnormal electrocardiogram with clinical significance
• Use any prescription drugs, Chinese herbs and/or OTC or health products within 2 weeks before starting the administration.
• Women who are pregnant or breastfeeding, or subjects with positive pregnancy test results at the time of screening or at baseline, or who plan to become pregnant during the study period or within 30 days after the end of the study.
• Subjects who have any factors deemed unsuitable for participation in this study by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SAD:100mg; Participants received single PO dose of GFH312 100 mg.	Drug: GFH312 100 mg; Participants receive single dose of GFH312 100 mg orally; Other Names: GFH312
Experimental: SAD:200mg; Participants received single PO dose of GFH312 200 mg.	Drug: GFH312 200 mg; Participants receive single dose of GFH312 200 mg orally; Other Names: GFH312
Experimental: MAD:120mg; Participants received multiple PO doses of GFH312 120 mg for 14 days.	Drug: GFH312 120mg; Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days; Other Names: GFH312
Placebo Comparator: Placebo; Participants receiving placebo matching with the GFH312 dose groups	Other: Placebo; Participants receive placebo matching with GFH312

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to peak drug concentration (Tmax) of GFH312	The time it takes for a drug to reach the maximum concentration (Cmax) after administration of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
Terminal Elimination Half Life (t1/2) of GFH312	The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4; for multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of GFH312	The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of GFH312	The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
The apparent systemic (or total body) clearance from plasma (or serum or blood (CL/F) following extravascular administration of GFH312	The systemic clearance (CL) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4; for multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
The apparent volume of distribution during the terminal elimination phase (Vd/F) following extravascular administration of GFH312	The volume of distribution was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4; for multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
The observed maximum plasma (or serum or blood) concentration following drug administration at steady state (Cmax,ss)	Observed maximum concentration in the dosing interval at steady state	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
The lowest plasma (or serum or blood) concentration observed during a dosing interval at steady state (Cmin,ss)	Observed minimum concentration in the dosing interval at steady state.	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Time to reach maximum concentration in the dosing interval at steady state (Tmax,ss)	If the same Cmax concentration occurs at different time points, Tmax is assigned to the first occurrence of Cmax.	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
The area under the plasma (or serum or blood) concentration-time curve from time zero to the end of the dosing interval tau (AUCtau,ss)	Dose-normalized AUC0- τ, calculated as AUC0-τ divided by actual dose administered.	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Maximum Observed Plasma Concentration (Cmax) of GFH312	The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of GFH312.	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug.	up to 30 days after the last study drug administration

Collaborators and Investigators

• Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.
• Investigators: Principal Investigator: LU Yongning, PHD, Wuhan Union Hospital, China

Study record dates

Study Major Dates

• Study Start (Actual): November 29, 2022
• Primary Completion (Actual): February 13, 2023
• Study Completion (Actual): May 30, 2023

Study Registration Dates

• First Submitted: July 6, 2023
• First Submitted That Met QC Criteria: August 6, 2023
• First Posted (Actual): August 14, 2023

Study Record Updates

• Last Update Posted (Actual): August 23, 2023
• Last Update Submitted That Met QC Criteria: August 20, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: GFH312X1102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No